Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CODEX-guided precision treatment in BRCA-negative platinum-resistant recurrent ovarian cancer
ChiCTR2000036406Phase 2Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Oct 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab, paclitaxel and bevacizumab in ovarian cancer (4 arms), sponsored by Renji Hospital. Primary endpoint: Objective response rate. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
sintilimabpaclitaxelbevacizumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR2000036406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036406.